News

Gambro is 49% owned by Investor AB and remaining by EQT IV. Terumo will use available cash and bank loans to complete the deal, which is expected to

Aptiv Solutions provides drug development consulting and regulatory services essential to progress a development program from research to product approval. Ricerca CEO Ian Lennox said the Fulcrum Pharma

The agreement allows Amyris to own and distribute the produced products under the collaboration. Amyris and Antibioticos commenced test fermentation runs in January 2011, and, based on the

Proteonomix is a biotechnology company engaged in developing therapeutics based upon the use of human cells and their derivatives. Proteonomix further intends to use THOR BioPharma to serve

The co-primary endpoints will be progression-free survival and overall survival and the company expects to commence this Phase 3 clinical trial of Folotyn in 2011. Allos chief medical

Esbriet is a small-molecule drug which is orally active, and inhibits the synthesis of TGF-beta, a chemical mediator that controls several cell functions and is important in fibrosis.

Under the pact, both the companies are expected to develop drugs for the treatment of autoimmune diseases like psoriasis, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Further,

The multi-centre, randomised, double-blind proof-of-concept clinical trial will compare the use of a catheter irrigation solution containing NVC-422 versus the use of a saline irrigation, the commonly used

IPI-926 is a novel, oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway. The activation of the Hedgehog pathway is believed to be involved in